Major histocompatibility complex class II and T-cell receptor complex

The **major histocompatibility complex class II and T-cell receptor complex** is a molecular assembly that plays a central role in adaptive immunity. **MHC class II molecules** are expressed primarily on antigen-presenting cells (APCs) and bind to processed peptide antigens derived from extracellular proteins. These complexed peptide-MHC II (pMHC II) molecules are presented on the cell surface, where they are specifically recognized by the **T-cell receptor (TCR)** on CD4+ helper T cells[1][3][6]. The interaction between a TCR and pMHC II triggers intracellular signaling via the CD3 complex, resulting in T-cell activation, proliferation, and differentiation[2][4][7]. This process is critical for the initiation of immune responses, including antibody production and cellular immunity. Crystallography and cryo-EM have revealed that the **TCR docks diagonally across the peptide-bound MHC II groove**, making contacts via the complementarity-determining regions (CDRs) in a highly specific but degenerate manner, allowing for broad antigen recognition[3][5][6][7]. As a *therapeutic target*, the pMHC II–TCR complex itself is rarely targeted directly by approved drugs, but components of its signaling pathway (notably, costimulatory molecules and CD3) are important pharmacologic targets for immunosuppression in transplantation, autoimmunity, and oncology[7]. Disruption or abnormal recognition by this complex can cause **autoimmune diseases**, while hijacking it is a central feature of immune evasion in cancer and infection. This target is *overly broad* and represents not a single gene or protein, but a transient multimeric complex formed between an MHC class II molecule (HLA-DR, -DP, or -DQ in humans), a peptide antigen, and a T-cell receptor (a specific heterodimer on T cells)[3][4]. Each of these components can be considered a distinct therapeutic target, but the tri-molecular complex is a functional immunological entity rather than a standard molecular target. In most structured databases, "MHC class II" and "T-cell receptor" would be indexed separately, and more precise entries would refer to a particular HLA allele or TCR clonotype. If you need structured data for individual molecular targets, consider searching for: - "Major histocompatibility complex class II" (MHC-II, HLA-DR, HLA-DQ, HLA-DP) - "T-cell receptor" (TCR alpha/beta, TCR gamma/delta) For the MHC class II–TCR complex, structured information is often more appropriately used for immunologic modeling rather than drug targeting.

Other names

MHC class II–TCR complexpMHCII–TCR complexpeptide-MHC class II–T-cell receptor complexMHC-II–TCR complex

Inhibition of T-cell activation by blocking costimulatory signaling (e.g., CTLA4-Ig drugs); Suppression of TCR-mediated activation (e.g., anti-CD3 antibodies); Modulation of peptide presentation (e.g., HLA class II blockers—experimental)